In addition, there were some limitations in our study as follows: (1) Lacking of publicly available datasets to perform in silico analysis and support these findings; (2) lacking in vivo experiments to validate the oncogenic role of ADAMTS9-AS1 in glioma; and (3) lacking of investigation on the effects of ADAMTS9-AS1 on drug resistance during glioma treatment; which will be our next study goal. This evidence concerns the gene ADAMTS9 and central nervous system cancer.